Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPoD-790 phase 2 study of ixazomib + pomalidomide + dexamethasone in relapsed or refractory multiple myeloma after daratumumab, lenalidomide, and bortezomib
MOH_2020-07-26_009107Phase 2Active, not recruiting
- Sponsor
- ד"ר יעל כהן
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by ד"ר יעל כהן. Started Apr 2020; status: active, not recruiting.
02
Drugs
ixazomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2020-07-26_009107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-26_009107.